1	Asymmetry of fibrillar plaque burden in amyloid mouse
2	models

4	Christian Sacher ¹ , Tanja Blume ^{1,2} , Leonie Beyer ¹ , Gloria Biechele ¹ , Julia
5	Sauerbeck ¹ , Florian Eckenweber ¹ , Maximilian Deussing ¹ , Carola Focke ¹ , Samira
6	Parhizkar ³ , Simon Lindner ¹ , Franz-Josef Gildehaus ¹ , Barbara von Ungern-
7	Sternberg ¹ , Karlheinz Baumann ⁴ , Sabina Tahirovic ² , Gernot Kleinberger ^{3,5,6} ,
8	Michael Willem ³ , Christian Haass ^{2,3,5} , Peter Bartenstein ¹ , Paul Cumming ^{7,8} , Axel
9	Rominger ^{1,7} , Jochen Herms ^{2,5,9} , Matthias Brendel ^{1,5}
10	¹ Dept. of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich Germany
11	² DZNE - German Center for Neurodegenerative Diseases, Munich, Germany
12 13	³ Chair of Metabolic Biochemistry, Biomedical Center (BMC), Faculty of Medicine, LMU Munich, Munich, Germany
14 15 16	⁴ Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd., Basel, Switzerland ⁵ Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
17	⁶ ISAR Bioscience GmbH, Planegg, Germany
18	⁷ Department of Nuclear Medicine, Inselspital, University Hospital Bern, Bern, Switzerland
19 20	⁸ School of Psychology and Counselling and IHBI, Queensland University of Technology, Brisbane, Australia
21	⁹ Center of Neuropathology and Prion Research, University of Munich, Munich Germany
22	
23	Abbreviated title: Aβ plaque asymmetry in mice
24 25 26 27	Corresponding author: Dr. Matthias Brendel; Department of Nuclear Medicine, University of Munich; Marchioninistraße 15, 81377 Munich, Germany; Phone:+49(0)89440077646; E-Mail:matthias.brendel@med.uni-muenchen.de
28 29 30	First author: Christian Sacher (medical student); Department of Nuclear Medicine; LMU Munich, Germany; Phone:+49(0)1623878661; E-Mail:christian.sacher@med.uni-muenchen.de
31	
32	Word count: 5000
33 34 35 36 37 38 39	

1 ABSTRACT

2 **Objective:** Asymmetries of amyloid- β (A β) burden, are well-known in Alzheimer's 3 disease (AD), but did not receive attention in A β mouse models of AD. Therefore, we 4 investigated A β -asymmetries in A β mouse models examined by A β - small animal 5 positron-emission-tomography (PET) and tested if such asymmetries have an 6 association with microglial activation. Methods: 523 cross-sectional AB-PET scans of five different Aβ mouse models (APP/PS1, PS2APP, APP-SL70, App^{NL-G-F} and 7 8 APPswe) were analyzed together with 136 18kDa translocator protein (TSPO)-PET 9 scans for microglial activation. The asymmetry index (AI) was calculated between 10 tracer uptake in both hemispheres. Als of Aβ-PET were analyzed in correlation with 11 TSPO-PET Als. Extrapolated required sample sizes were compared between 12 analyses of single and combined hemispheres. Results: Relevant asymmetries of 13 Aß deposition were identified in $\geq 30\%$ of all investigated mice. There was a 14 significant correlation between AIs of Aβ-PET and TSPO-PET in four investigated Aβ 15 mouse models (APP/PS1: R=0.593, P=0.001; PS2APP: R=0.485, P=0.019; APP-SL70: R=0.410, P=0.037; App^{NL-G-F}: R=0.385, P=0.002). Asymmetry was associated 16 17 with higher variance of tracer uptake in single hemispheres, leading to higher 18 required sample sizes. **Conclusions:** Asymmetry of fibrillar plaque neuropathology 19 occurs frequently in AB mouse models and acts as a potential confounder in 20 experimental designs. Concomitant asymmetry of microglial activation indicates a 21 neuroinflammatory component to hemispheric predominance of fibrillary amyloidosis.

22

23 Key words: asymmetry, amyloid, microglia, mouse models

- 24
- 25

26

1 INTRODUCTION

2 Alzheimer disease (AD) is the most frequent neurodegenerative disease, with 3 burgeoning incidence rates due to the rising life expectancy in most of the world (1). 4 The neuropathology of AD is histologically characterized by the triad of accumulation 5 of amyloid- β peptide (A β) as extracellular plaques, fibrillary tau aggregates within 6 neurons, and the activation of multiple neuroinflammatory pathways, which is 7 mediated by activated microglia expressing high levels of the marker 18-kDa 8 translocator protein (TSPO) (2). Animal models that accurately reflect this complex 9 pathology are indispensable for contemporary preclinical research into the molecular 10 mechanisms of AD. In this context, a range of different overexpressing and knock-in 11 Aß mouse models have been established for molecular imaging with positron 12 emission tomography (PET). In recent PET studies, increased binding of the AB tracer ¹⁸F-florbetaben (¹⁸F-FBB) and the TSPO tracer ¹⁸F-GE-180 were firmly 13 14 established by longitudinal in vivo quantification of cerebral amyloidosis and 15 microglial activation in various A β mouse models of AD (3-5). In humans, an 16 asymmetric spatial distribution of neuropathological AD hallmarks is frequently 17 discovered by PET studies in vivo (6-8). A recent human PET study has already 18 shown that asymmetric spatial distributions of Aß plaques are positively correlated 19 with ipsilateral neurodegeneration (8). However, no study has hitherto investigated 20 systematically the asymmetry in A β mouse models of AD. While a large scaled 21 investigation of this phenomenon by histopathological investigations would be of high 22 economic effort and difficult in terms of standardization, in vivo PET imaging methods 23 should afford the means to compare readily the AB plaque burden in both 24 hemispheres of individual animals.

Given this background, our aim was to investigate the occurrence of asymmetric fibrillar A β deposition in the well-established A β mouse models APP/PS1, PS2APP, APP-SL70, *App^{NL-G-F}* and APPswe. Using a large series of historical ¹⁸F-FBB A β -PET recordings, we tested for asymmetric A β deposition, while

1 considering age as a predictive variable. We also made sample size estimations for 2 detecting asymmetric A β , and tested the hypothesis that A β asymmetry is associated 3 with ipsilateral microglial activation as assessed by ¹⁸F-GE-180 TSPO-PET.

4

5 MARTERIAL AND METHODS

6 Experimental Design

7 All experiments were performed in compliance with the National Guidelines 8 for Animal Protection, Germany and with the approval of the regional animal 9 committee (Regierung Oberbayern) and were overseen by a veterinarian. Animals 10 were housed in a temperature- and humidity-controlled environment with 12h light-11 dark cycle, with free access to food (Sniff, Soest, Germany) and water. A detailed 12 overview of the investigated mouse cohorts is given in Supplemental Table 1. All 13 PET raw data originated from previous in-house studies (cited below) conducted on 14 the same Inveon small animal PET under identical acquisition parameters. 87% of 15 the mice investigated were female. APP/PS1 and APPswe comprised only female 16 mice, whereas PS2APP, APP-SL70, and App^{NL-G-F} included both sexes. All raw data 17 were reprocessed to guarantee optimal agreement of spatial and radioactivity 18 normalization. Either descriptive datasets or control groups of therapy/ genotype 19 studies were included. From each investigated mouse, the degree of asymmetry in 20 Aβ-PET and TSPO-PET was assessed by volume-of-interest based quantification in 21 both cerebral hemispheres.

22

23 Animal Models

APP/PS1 (APPPS1-21): This transgenic mouse model was generated on a C57BL/ 6J genetic background that coexpresses KM670/671NL mutated amyloid precursor protein and L166P mutated presenilin 1 under the control of a neuronspecific Thy1 promoter. Cerebral amyloidosis in this model starts at 6–8 weeks of age (9). Historical ¹⁸F-FBB data from 41 scans of APP/PS1 mice imaged at four different ages (3, 6, 9 and 12 months) were reprocessed (10). 27 contemporaneous
 ¹⁸F-GE-180 scans were available.

3 PS2APP (APPswe/PS2): The transgenic B6.PS2APP (line B6.152H) is 4 homozygous both for human presenilin (PS) 2, the N141I mutation, and the human 5 amyloid precursor protein (APP) K670N/M671L mutation (11). Homozygous 6 B6.PS2APP mice show first appearance of plaques in the cerebral cortex and 7 hippocampus at 5–6 months of age (12). Historical ¹⁸F-FBB data from 147 scans of 8 PS2APP mice imaged at four different age ranges (6-8, 9-10, 11-14 and 15-17 9 months) were reprocessed (13,14). 23 contemporaneous ¹⁸F-GE-180 scans from 10 these mice were likewise reprocessed by standard methods.

11 APP-SL70: The PS1 knock-in line was generated by introducing two-point 12 mutations in the wild-type mouse PSEN1, corresponding to the mutations M233T and 13 L235P. The APP751SL mouse overexpresses human APP751 carrying the London 14 (V717I) and Swedish (K670N/M671L) mutations under the control of the Thy1 15 promoter. Aß deposits appear as early as 2.5 months of age in these mice (15). 16 Historical ¹⁸F-FBB data from 208 scans of APP-SL70 mice imaged at four different 17 ages (4–6, 7–9, 10–12 and 13–15 months), deriving from a descriptive observational 18 study (16), along with control scans from an as yet unpublished therapy study were 19 reprocessed. 26 contemporaneous ¹⁸F-GE-180 scans were available in this group.

App^{NL-G-F}(App^{NL-G-F}/App^{NL-G-F}): The knock-in mouse model App^{NL-G-F} carries a mutant 20 21 APP gene encoding the humanized A β sequence (G601R, F606Y, and R609H) with 22 three pathogenic mutations, namely Swedish (KM595/596NL), Beyreuther/Iberian (I641F), and Arctic (E618G). Homozygotic App^{NL-G-F} mice progressively exhibit 23 24 widespread A β accumulation from two months of age (17,18). Historical ¹⁸F-FBB data from 55 scans of homozygotic App^{NL-G-F} mice imaged at four different ages (2.5, 5.0, 25 26 7.5 and 10 months) were reprocessed (3). 55 contemporaneous ¹⁸F-GE-180 scans 27 were available in this data set.

28 *APPswe:* Transgenic mice overexpressing human APP with the Swedish double

mutation (K670N, M671L) driven by the mouse Thy1.2 promoter were generated as described earlier (*11*). Mice heterozygous for the transgene begin accumulating β amyloid at approximately nine months of age and develop β -amyloid plaques at twelve months of age, mainly in the cortical mantle. Historical ¹⁸F-FBB data from 72 scans of APPswe mice imaged at three different age ranges (9–12, 13–16 and 17–20 months) were reanalyzed (*19,20*). Contemporaneous ¹⁸F-GE-180 scans were not available for these mice.

- 8 *C57BI/6:* Historical and unpublished ¹⁸F-FBB data from 27 scans of C57BI/6 mice
 9 (WT) were reprocessed and served as control material (age: 2.5-16 months).
- 10

11 **PET Imaging**

12 PET Data Acquisition, Reconstruction and Post-Processing: For all PET 13 procedures, radiochemistry, data acquisition, and image pre-processing were 14 conducted according to an established, standardized protocol (4,21). In brief, ¹⁸F-15 FBB Aβ PET recordings (average dose: 11.4±2.0 MBg) with an emission window of 16 30–60 min after injection were obtained to measure fibrillar cerebral amyloidosis. ¹⁸F-17 GE-180 TSPO PET recordings (average dose: 11.1±2.0 MBg) with an emission 18 window of 60-90 min after injection were performed for assessment of cerebral 19 TSPO expression. Anesthesia was maintained from just before tracer injection to the 20 end of the imaging time window.

21 PET Image Analysis: We performed all analyses using PMOD (version 3.5; 22 PMOD technologies). Normalization of emission images to standardized uptake 23 value ratio (SUVR) images was performed using previously validated white matter 24 (WM) reference regions for transgenic amyloid mouse models (APP/PS1, PS2APP, 25 APP-SL70 and APPswe) (4,21). For the knock-in mouse line App^{NL-G-F} , the 26 mesencephalic periaqueductal gray (PAG) was used as reference region, as recently 27 published (3). Two bilateral telencephalic volumes of interest (VOIs) (containing 28 cortex and hippocampus) comprising 50 mm³ each, were employed for calculation of

SUVR_{Forebrain/WM} or SUVR_{Forebrain/PAG}. For each scan, the hemispheric asymmetry index
 (AI) was calculated for ¹⁸F-FBB or ¹⁸F-GE-180 scans using the formula:

 $AI [\%] = 200 \times (R - L) / (R + L)$

3

4

5 Statistical Analysis

6 95% and 99% confidence intervals (CI) of ¹⁸F-FBB AIs in normal C57BL/6 7 mice were calculated. Aβ mouse model ¹⁸F-FBB scans were judged as asymmetric 8 when they exceeded the 95%-CI (moderate asymmetry) or the 99%-CI (strong 9 asymmetry) of C57BL/6 mice. Significant ¹⁸F-FBB |AIs| (absolute magnitude) were 10 correlated with age for each AB mouse model to evaluate age-dependency of 11 asymmetric plaque distribution. For each Aß mouse model, age-independent 12 lateralized plaque distributions were compared by a Chi-square test to test for left or 13 right predominance of AB deposition. Frequency of strong asymmetries were 14 calculated in groups of comparable age for AB mouse models and correlated with 15 coefficients of variance (CoV) of SUVR in the same groups of mice. Pearson's 16 coefficients of correlation (R) were calculated for the latter analyses and for correlation analyses between ¹⁸F-FBB AIs and age as well as between ¹⁸F-FBB AIs 17 18 and ¹⁸F-GE-180 Als. Hypothetical 2-sided t-test of independent measures were 19 performed in order to perform sample sizes calculations in comparison of SUVR in 20 single hemispheres and in combined hemispheres using G*Power (V3.1.9.2, Kiel, 21 Germany). We used a given 5% therapy effect on SUVR at a power $(1-\beta)$ of 0.80 22 and type one error of α =0.05. A *P*-value of less than 0.05 was considered to be 23 significant for rejection of the null hypothesis. SPSS 25 statistics (IBM Deutschland 24 GmbH, Ehningen, Germany) was used for all statistical tests.

25

26 **RESULTS**

27 Asymmetric Plaque Distribution is Frequent in Aβ Mouse Models

28

First, we defined an asymmetry threshold based on PET measurements in

1 WT mice to establish real A β asymmetry, without bias in the spatial normalization or 2 by physiological variability in tracer uptake. The 95%-Cl of ¹⁸F-FBB Als in C57BL/6 3 mice was -3.6% (right lateralization) to 3.6% (left lateralization) and defined the 4 threshold for moderate Aβ asymmetry. The 99%-Cl of ¹⁸F-FBB AIs in C57BL/6 was -5 4.0% (right lateralization) to 4.5% (left lateralization) and defined the threshold for 6 strong Aβ asymmetry. Using these thresholds, 40% (L=21%; R=19%; 95%-CI) of all 7 amyloid accumulating mice showed moderate asymmetry and 30% (L=14%; R=16%; 8 99%-CI) showed strong asymmetry of ¹⁸F-FBB forebrain uptake (Figure 1). There 9 was no significant hemispheric predominance across the whole cohort of different Aß 10 mouse models. A detailed overview is provided in Supplemental Table 1.

11 Highest frequency of moderate $A\beta$ -PET asymmetry was observed in PS2APP 12 and App^{NL-G-F} mice (49% each). Strong A β -PET asymmetry was most frequently 13 observed in PS2APP and APP/PS1 mice (37% each). Lowest frequency of Aβ-PET 14 asymmetry was present in APPswe mice, in which 32% of scans indicated moderate 15 and 24% showed strong asymmetry. A significant left-hemispheric predominance of 16 Aβ deposition was detected in the PS2APP mice (χ^2 =4.7; P=0.030; Chi-square test), 17 whereas a significant right-hemispheric predominance of A_β deposition was seen in 18 APPswe mice (χ^2 =15; P=0.0001; Chi-square test). There was no significant 19 association between age and asymmetric Aß distribution in any Aß mouse model 20 (Figure 2). In summary, asymmetry of plaque burden was frequently observed in all 21 studied Aβ mouse models, but with different magnitudes and side predilections.

22

Asymmetric Plaque Burden Impacts the Sufficient Sample Sizes in Preclinical Trials

Given the observed asymmetries in all $A\beta$ mouse models studied, we hypothesized that measures in single hemispheres (as are typically examined by histological methods) would suffer from higher variance, subsequently leading to higher required sample sizes in preclinical trials when compared to combined

measures of both hemispheres, as are obtained by PET. CoV were positively 1 2 associated with the frequency of plaque burden asymmetry (99%-CI) in groups of 3 comparable age in different A β mouse models (*R*=0.380, *P*=0.027, Figure 3A). CoV 4 by groups of comparable age in the different A β mouse models were 4.3±1.2% for 5 separate measures of left and right hemispheres and significantly lower for the 6 combined quantification of both hemispheres (3.9 \pm 1.2%; P = left vs. both: 0.0003/ 7 right vs. both: 0.0007; paired *t*-test). Calculated sample sizes for detection of a 5% 8 therapy effect on SUVR at a power $(1-\beta)$ of 0.80 and type one error of α =0.05 were 9 n=14.1 for separate measures for the left hemisphere, n=13.9 for separate measures 10 of the right hemisphere, and n=11.9 for combined quantification of both hemispheres 11 (P=0.0020/0.0016; paired t-test). Required sample sizes as a function of power were 12 consistently higher for calculation with left (Figure 3B) and right (Figure 3C) 13 hemispheric values when compared to combined quantification of both hemispheres. 14 The average reductions of required sample sizes for combined quantification of both 15 hemispheres were 2.1±0.6 (vs. left) and 1.8±0.5 (vs. right). These results indicate 16 that asymmetry of plaque burden in AB mouse models considerably increases 17 required sample sizes when hemispheres are analyzed separately.

18

19 Asymmetric Plaque Burden is Associated with Ipsilateral Glial Activation

20 Several studies have revealed associations between amyloid deposition and 21 microglial activation in A β mouse models (3,4,16). However, it has not hitherto been 22 investigated if microglial activation follows any asymmetry of plaque burden, or if the 23 microgliosis is globally distributed. Hence, we made use of contemporaneous TSPO-24 PET data for correlation analysis with lateralization to Aβ-PET. Significant positive 25 associations between asymmetric AB deposition and ipsilateral lateralization of 26 TSPO expression were observed in all four Aß mouse models. The magnitude of 27 correlation between asymmetric Aβ-PET and ipsilateralized TSPO-PET uptake was 28 similar among APP/PS1 (R=0.593; P=0.001; n=27; Pearson's correlation), PS2APP

1 (*R*=0.485; *P*=0.019; n=23; Pearson's correlation), APP-SL70 (*R*=0.410; *P*=0.037; 2 n=26; Pearson's correlation), and App^{NL-G-F} (*R*=0.385; *P*=0.002; n=60; Pearson's 3 correlation) mice. Taken together these results clearly indicate a spatial association 4 between asymmetric distribution of fibrillar A β plaques and ipsilateral microglial 5 activation.

6

7 DISCUSSION

8 In contrast to human investigations on asymmetrical Aß distribution in AD 9 (6, 8, 22), only scantly evidence is available for the presence of A β asymmetry in 10 mouse models (19,23). We present the first large-scale preclinical in vivo 11 investigation of fibrillar plaque burden asymmetry by standardized evaluation of PET 12 data. With respect to animal welfare guidelines, in particular reduction of animal 13 numbers in accordance with the 3R principle, we used scans from various earlier 14 studies, this avoiding any requirement for additional animal experiments to test our 15 hypotheses.

16 First, we endeavored to establish a reasonable threshold of lateralized Aβ-17 PET signal to exclude asymmetry findings driven by reasons other than AB 18 pathology. To this end, we used Aβ-PET data of C57BL/6 WT mice, as they are not 19 known to manifest any Aβ accumulation. Minor asymmetry of FBB tracer uptake in 20 WT mice could be attributed to factors such as differences in cerebral blood flow, 21 differing hemispheric volumes, or methodological issues such as lateralized spill-over 22 of bone uptake, imperfect attenuation correction, or bias in spatial normalization. 23 Hence, we used the 95% and 99% CIs of ¹⁸F-FBB AIs in WT to discern moderate 24 and strong asymmetry in the groups of A β accumulating mice. By these criteria, 40% 25 of all Aß accumulating mice revealed moderate asymmetry, and 30% showed 26 strongly asymmetric Aβ deposition, but without evidence for a general lateralization 27 across all AD models. Nevertheless, two out of five investigated amyloid models

1 revealed significant lateralization of A β plaque distribution to A β -PET. There was a 2 significant left-hemispheric predominance of A^β deposition in PS2APP mice, but a 3 significant right-hemispheric predominance in APPswe mice. While molecular 4 explanations and causal mechanisms giving rise to this phenomenon are presently 5 unknown, we contend that this is a real phenomenon requiring special consideration when comparing data from different AB mouse models of AD. For example, a 6 7 comparison of exclusively right hemisphere read-outs, as might be obtained by 8 histological analysis, between APPswe and PS2APP could cause false negative 9 findings, and likewise for the left hemisphere. The highest frequency of asymmetry 10 was observed in A β models with a Presenilin mutation (PS2APP and APP/PS1), 11 indicating that involvement of this gene might increase the probability of asymmetric 12 plaque burden. Variable expression of APP mRNA across different PS2APP mice is 13 already postulated to be a key determinant of variance in individual AB deposition 14 (12); therefore we speculate that this phenomenon could likewise hold true for 15 differences between hemispheres.

16 By making sample size estimations, we established that the observed 17 asymmetries of fibrillar plaque burden are potentially relevant to the design of 18 preclinical trials. Importantly, the calculated sample sizes sufficient to detect relevant 19 therapeutic effects, which are comparable to those of earlier drug trials in these AB 20 mouse models (13,20), were significantly higher when only single hemispheres were 21 analyzed, as opposed to combined measurement of both hemispheres. As Aβ-PET 22 and histology markers for fibrillar A^β were strongly intercorrelated in previous studies 23 (10,19,24), we assume that asymmetry effects on required sample sizes should also 24 hold true for stand-alone histological or biochemical analyses. This conjecture 25 remains to be demonstrated, since usual practice is to process one hemisphere for 26 histology and one for biochemistry. Aβ-PET findings at the terminal time-point could 27 help to identify mice with asymmetric plaque burden, which would allow consecutive 28 adjustment of measures by different modalities in separate hemispheres.

1 Next, we investigated whether asymmetric A β distributions occur in an age-2 dependent manner. Our cross-sectional analysis of historical PET data did not 3 indicate any significant association of AI with age among the five A β mouse models. 4 This is consistent with our earlier longitudinal ¹⁸F-FBB-PET findings in APPswe, were we incidentally noticed that some animals showed consistently right-sided plaque 5 6 asymmetry between 13 and 20 months of age. More precisely, the magnitude of 7 asymmetry in SUVR increased with age, but with no temporal dependence of the AI 8 per se (19). In conclusion, A β asymmetries, when present, are established at the 9 onset of plaque deposition.

10 We suppose that there are hitherto few reports on asymmetric plaque burden 11 in Aβ mouse models due to the logistic difficulty of conducting onerous histological 12 analysis of both hemispheres for sufficient numbers of animals. We performed a 13 meta-analysis of the most recent 56 papers from journals with impact factor > 4 14 published in the interval 2016 to 2019 with the key words "amyloid, mouse, model, 15 AD". 38% (21/56) of these papers provided detailed information about use of different 16 hemispheres for histology and biochemistry. 81% among those (17/21) assigned a 17 specific hemisphere to a given modality, whereas only 19% (4/21) performed 18 randomization of hemispheres to different modalities. Most of the remaining 35 19 papers likewise split hemispheres to different modalities, but without detailed 20 information about the selection process. Immunohistochemistry with AB antibodies 21 like 6E10 was most frequently used to assess fibrillar plaques in vitro, whereas other 22 studies used histological staining with methoxy-X04 or thioflavin S (14,25). These 23 generally reported immunohistochemistry/histology findings for Aß studies 24 quantification from a few representative brain slices of a single hemisphere, whereas 25 the other hemisphere was typically reserved for biochemical assays such as 26 Enzyme-linked Immunosorbent Assay or western blotting, which are not compatible 27 with tissue fixation. Therefore, evaluation of intra-animal asymmetry in vitro was not 28 feasible due to allocation of the hemispheres for different kinds of analyses. In summary, potential asymmetries of fibrillar plaque burden were only sparsely
 considered in published papers during the recent years.

3 Contrary to the case in vitro, AB-PET allows convenient quantification of 4 amyloid pathology in both whole hemispheres, with the caveat that the PET method 5 has inherent limitations in spatial resolution (26,27). Therefore, PET quantification of 6 small brain areas can be challenging, although asymmetry assessment A β plaque 7 burden in large forebrain regions is a rather robust measure. Thus, conducting non-8 invasive PET examination prior to assignment of hemispheres to different terminal 9 biochemical or histological experiments could help to identify and adjust for relevant 10 asymmetries of plaque burden. This should encourage the combined use of PET 11 together with immuno(histochemistry) and biochemistry read outs.

12 Another focus of our study was to investigate the relationship between 13 lateralized A_β deposition and microglial activation. Previous studies of our laboratory 14 have already shown close correlations between fibrillar amyloidosis and TSPO 15 expression in APP/PS1, PS2APP, APP-SL70 and App^{NL-G-F} mice (3,4,10,16). 16 Although we acknowledge that it was anticipated from these earlier findings, we now 17 show for the first time that microglial activation occurs concomitantly in the 18 hemisphere ipsilateral with predominant fibrillar amyloidosis. This association further 19 strengthens the hypothesis that initial fibrillar A β accumulation triggers 20 neuroinflammation mediated by activated microglia (28). Another recently published 21 study has also demonstrated a link between amyloidosis and neuroinflammation 22 based on comparative profiling of cortical gene expression in AD patients and an AB 23 mouse model (29). Comparisons of gene expression between hemispheres of mice 24 with asymmetric amyloidosis could give new insights into the molecular pathways 25 and causal mechanisms underlying asymmetry in AD. PET screening could guide the 26 selection for detailed study of mice with strong asymmetries.

27

28 CONCLUSION

1 Nearly a third of AB mice show distinct left- or right-asymmetry in the 2 deposition of cerebral amyloid. This phenomenon is neglected in the majority of 3 current studies in Aß mice and calls for consideration in the planning and design of 4 preclinical trials, especially when single hemispheres are investigated by methods ex 5 *vivo*. The lack of age-dependency on asymmetric Aβ distribution implies that genetic 6 factors underlie the development of lateralized amyloidosis in AD model mice. There 7 is a clear association between asymmetries of glial activation and fibrillar amyloidosis 8 in all A β mouse models investigated in this study, further strengthening the 9 hypothesis that neuroinflammatory response to fibrillar AB contribute to the 10 development of pathology in these mice.

11

12 **DISCLOSURE**

13 C.H. collaborates with Denali Therapeutics, participated on one advisory 14 board meeting of Biogen, and received a speaker honorarium from Novartis and 15 Roche. C.H. is chief advisor of ISAR Bioscience. P.B., A.R. and M.B. received 16 speaking honoraria from Life Molecular Imaging and GE healthcare. M.B. is an 17 advisor of Life Molecular Imaging. No other potential conflicts of interest relevant to 18 this article exist.

19

20 ACKNOWLEDGEMENTS

C.H. is supported by the Koselleck Project HA1737/16-1 of the DFG, the
Helmholtz-Gemeinschaft (Zukunftsthema"Immunology and Inflammation"(ZT-0027))
and the Cure Alzheimer's fund. The work was supported by the Deutsche
Forschungsgemeinschaft (M.B. and A.R. BR4580/1-1&RO5194/1-1). The APPPS1
colony was established from a breeding pair kindly provided by M. Jucker (HertieInstitute for Clinical Brain Research, University of Tübingen and DZNE-Tübingen).
APPswe, PS2APP and APP-SL70 mice were provided by Hoffmann-La Roche.

1	APP ^{NL-G-F} mice were provided by RIKEN BRC through the National Bio-Resource
2	Project of the MEXT, Japan. GE Healthcare made GE-180 cassettes available
3	through an early-access model.

5 QUESTION: Do amyloid mouse models have asymmetric plaque distribution and asymmetric6 neuroinflammation?

7

8 PERTINENT FINDINGS: Asymmetry in these amyloid mouse models is frequent and
9 statistically relevant for planning of observational and interventional trials in these mice.
10 Moreover, asymmetries of fibrillar plaque burden and glial activation are positively correlated.

11

TRANSLATIONAL IMPLICATIONS: Lateralized distribution of fibrillar plaques is insufficiently
 considered in experimental studies with amyloid mouse models and a potential confounder in
 preclinical phases of drug development.

15

16 **REFERENCES**

17 1. Ziegler-Graham K, Brookmeyer R, Johnson E, Arrighi HM. Worldwide

18 variation in the doubling time of Alzheimer's disease incidence rates.

19 Alzheimers Dement. 2008;4:316-323.

20

21 2. Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in

Alzheimer's disease. *Lancet Neurol.* 2015;14:388-405.

23

24 **3.** Sacher C, Blume T, Beyer L, et al. Longitudinal PET Monitoring of

25 Amyloidosis and Microglial Activation in a Second-Generation Amyloid-beta

26 Mouse Model. J Nucl Med. 2019;60:1787-1793.

1	

2	4.	Brendel M, Probst F, Jaworska A, et al. Glial Activation and Glucose
3	Meta	bolism in a Transgenic Amyloid Mouse Model: A Triple-Tracer PET
4	Stud	y. <i>J Nucl Med.</i> 2016;57:954-960.
5		
6	5.	Sasaguri H, Nilsson P, Hashimoto S, et al. APP mouse models for
7	Alzhe	eimer's disease preclinical studies. The EMBO Journal. 2017;36:2473-
8	2487	
9		
10	6.	Ossenkoppele R, Schonhaut DR, Scholl M, et al. Tau PET patterns
11	mirro	r clinical and neuroanatomical variability in Alzheimer's disease. Brain.
12	2016	;139:1551-1567.
13		
14	7.	Tetzloff KA, Graff-Radford J, Martin PR, et al. Regional Distribution,
15	Asyn	nmetry, and Clinical Correlates of Tau Uptake on [18F]AV-1451 PET in
16	Atypi	cal Alzheimer's Disease. <i>J Alzheimers Dis.</i> 2018;62:1713-1724.
17		
18	8.	Frings L, Hellwig S, Spehl TS, et al. Asymmetries of amyloid-beta
19	burde	en and neuronal dysfunction are positively correlated in Alzheimer's
20	disea	se. <i>Brain.</i> 2015;138:3089-3099.
21		
22	9.	Radde R, Bolmont T, Kaeser SA, et al. Abeta42-driven cerebral
23	amyl	oidosis in transgenic mice reveals early and robust pathology. <i>EMBO</i>
24	Rep.	2006;7:940-946.
25		

1	10.	Parhizkar S, Arzberger T, Brendel M, et al. Loss of TREM2 function
2	increa	ases amyloid seeding but reduces plaque-associated ApoE. <i>Nat</i>
3	Neuro	osci. 2019;22:191-204.
4		
5	11.	Richards JG, Higgins GA, Ouagazzal AM, et al. PS2APP transgenic
6	mice,	coexpressing hPS2mut and hAPPswe, show age-related cognitive
7	defici	ts associated with discrete brain amyloid deposition and inflammation. J
8	Neuro	osci. 2003;23:8989-9003.
9		
10	12.	Ozmen L, Albientz A, Czech C, Jacobsen H. Expression of transgenic
11	APP	mRNA is the key determinant for beta-amyloid deposition in PS2APP
12	trans	genic mice. <i>Neurodegener Dis.</i> 2009;6:29-36.
13		
14	13.	Brendel M, Jaworska A, Overhoff F, et al. Efficacy of chronic BACE1
15	inhibi	tion in PS2APP mice depends on the regional Abeta deposition rate and
16	plaqu	e burden at treatment initiation. <i>Theranostics</i> . 2018;8:4957-4968.
17		
18	14.	Brendel M, Kleinberger G, Probst F, et al. Increase of TREM2 during
19	Aging	of an Alzheimer's Disease Mouse Model Is Paralleled by Microglial
20	Activa	ation and Amyloidosis. Front Aging Neurosci. 2017;9:8.
21		
22	15.	Blanchard V, Moussaoui S, Czech C, et al. Time sequence of
23	matu	ration of dystrophic neurites associated with Abeta deposits in APP/PS1
24	trans	genic mice. <i>Exp Neurol.</i> 2003;184:247-263.
25		

1	16.	Blume T, Focke C, Peters F, et al. Microglial response to increasing
2	amylo	oid load saturates with aging: a longitudinal dual tracer in vivo muPET-
3	study	. J Neuroinflammation. 2018;15:307.
4		
5	17.	Masuda A, Kobayashi Y, Kogo N, Saito T, Saido TC, Itohara S.
6	Cogn	itive deficits in single App knock-in mouse models. Neurobiol Learn
7	Mem.	2016;135:73-82.
8		
9	18.	Saito T, Matsuba Y, Mihira N, et al. Single App knock-in mouse models
10	of Alz	heimer's disease. <i>Nat Neurosci</i> . 2014;17:661-663.
11		
12	19.	Rominger A, Brendel M, Burgold S, et al. Longitudinal assessment of
13	cereb	ral beta-amyloid deposition in mice overexpressing Swedish mutant
14	beta-a	amyloid precursor protein using 18F-florbetaben PET. J Nucl Med.
15	2013;	54:1127-1134.
16		
17	20.	Brendel M, Jaworska A, Herms J, et al. Amyloid-PET predicts inhibition
18	of de	novo plaque formation upon chronic gamma-secretase modulator
19	treatn	nent. <i>Mol Psychiatry.</i> 2015;20:1179-1187.
20		
21	21.	Overhoff F, Brendel M, Jaworska A, et al. Automated Spatial Brain
22	Norm	alization and Hindbrain White Matter Reference Tissue Give Improved
23	[(18)F	-]-Florbetaben PET Quantitation in Alzheimer's Model Mice. Front
24	Neuro	osci. 2016;10:45.

1	22.	Raji CA, Becker JT, Tsopelas ND, et al. Characterizing regional
2	correla	ation, laterality and symmetry of amyloid deposition in mild cognitive
3	impair	ment and Alzheimer's disease with Pittsburgh Compound B. J Neurosci
4	Metho	ods. 2008;172:277-282.
5		
6	23.	Manook A, Yousefi BH, Willuweit A, et al. Small-animal PET imaging of
7	amylo	id-beta plaques with [11C]PiB and its multi-modal validation in an
8	APP/F	PS1 mouse model of Alzheimer's disease. <i>PLoS One.</i> 2012;7:e31310.
9		
10	24.	Brendel M, Jaworska A, Griessinger E, et al. Cross-sectional
11	compa	arison of small animal [18F]-florbetaben amyloid-PET between
12	transg	enic AD mouse models. <i>PLoS One.</i> 2015;10:e0116678.
13		
14	25.	Cho SM, Lee S, Yang SH, et al. Age-dependent inverse correlations in
15	CSF a	and plasma amyloid-beta(1-42) concentrations prior to amyloid plaque
16	depos	ition in the brain of 3xTg-AD mice. <i>Sci Rep</i> . 2016;6:20185.
17		
18	26.	Visser EP, Disselhorst JA, Brom M, et al. Spatial resolution and
19	sensit	ivity of the Inveon small-animal PET scanner. <i>J Nucl Med.</i> 2009;50:139-
20	147.	
21		
22	27.	Huisman MC, Reder S, Weber AW, Ziegler SI, Schwaiger M.
23	Perfor	mance evaluation of the Philips MOSAIC small animal PET scanner.
24	Eur J	Nucl Med Mol Imaging. 2007;34:532-540.
25		

1	28.	Monasor LS, Müller SA, Colombo A, et al. Fibrillar A β triggers
2	micro	glial proteome alterations and dysfunction in Alzheimer mouse models.
3	bioRx	<i>iv.</i> 2019:861146.
4		
5	29.	Castillo E, Leon J, Mazzei G, et al. Comparative profiling of cortical
6	gene	expression in Alzheimer's disease patients and mouse models
7	demo	nstrates a link between amyloidosis and neuroinflammation. Sci Rep.
8	2017;	7:17762.
9		




Figure 1 – Asymmetry of plaque distribution in amyloid mouse models. Forrest plot shows AI for a total of 523 amyloid PET scans in APP/PS1, PS2APP, APP-SL70, APPswe and *App^{NL-G-F}* mice. Lateralized plaque distributions were compared by a Chi-square test to test for left or right predominance in each mouse model. Representative PET SUVR-images show exemplary mice with right (APPSwe) and left (APP/PS1) asymmetry.




Figure 2 – Age dependency of asymmetric amyloid deposition. Asymmetry (|A||) is shown as a function of age for APP/PS1, PS2APP, APP-SL70, APPswe and App^{NL-G-F} mice. Datapoints with significant asymmetric ¹⁸F-FBB uptake (|A|| > 95%-Cl_{WT}; light area) indicate no relevant dependency on asymmetric plaque distribution on age in any of the mouse models. Values with symmetric distribution (grey area) were excluded from the correlation analysis.




Figure 3 – Statistical relevance of asymmetric plaque distribution in amyloid mouse models. (A) Association of higher coefficients of variation (CoV) in SUVR with higher frequency of asymmetry in age related groups of amyloid mouse models (see supplemental Table 1). (B, C) Required sample sizes as a function of power in comparison of analyses in single hemispheres and combined hemispheres (given effect of 5%, α =0.05, hypothetical 2-sided t-test of independent measures).




Figure 4 - Association between lateralized amyloid deposition and microglia activation. Correlations between AIs of amyloid and microglia PET in APP/PS1, PS2APP, APP-SL70 and *App^{NL-G-F}* mice show congruent asymmetry of both biomarkers. *R* indicates Pearson's coefficients of correlation.

					A	myloid-PE	т				TSPO-PET
Group			Moderate asymmetry (>/< 95%-Cl _{wT}) Strong asymmetry (>/< 99%-Cl _{wT})								
	Age (months)	n	Left (n, % per subgroup)	Left (n, % per model)	Right (n, % per subgroup)	Right (n, % per model)	Left (n, % per subgroup)	Left (n, % per model)	Right (n, % per subgroup)	Right (n, % per model)	n
	3	6	0 (0%)		0 (0%)		0 (0%)		0 (0%)		0
APP/PS1	6	14	3 (21%)	20%	3 (21%)	22%	2 (14%)	15%	3 (21%)	22%	14
	9	6	1 (16%)	2070	1 (17%)	2270	1 (17%)	1570	1 (17%)	22%	5
	12	15	4 (27%)		5 (33%)		3 (20%)		5 (33%)		8
	6 - 8	55	15 (27%)		12 (22%)		10 (18%)		9 (16%)		13
PS2APP	9 - 10	42	16 (38%)	30%	9 (21%)	19%	14 (33%)	0.404	9 (21%)	400/	10
	11 - 14	36	12 (33%)	30%	5 (14%)	19%	7 (19%)	21%	4 (11%)	16%	0
	15 - 17	14	1 (7%)		2 (20%)		0(0%)		2 (14%)		0
APP-	4 - 6	130	21 (16%)		20 (15%)		12 (9%)		16 (12%)		0
SL70	7 - 9	37	6 (16%)	18%	6 (16%)	16%	5 (14%)	100/	5 (14%)	13%	8
	10 - 12	31	8 (26%)	1070	7 (23%)	10%	6 (19%)	12%	5 (16%)	1370	10
	13 - 15	10	3 (30%)		1 (10%)		2 (20%)		1 (10%)		8
A NI GE	2.5	20	4 (20%)		5 (25%)		3 (15%)		4 (20%)		17
App ^{NL-G-F}	5	17	4 (24%)	29%	3 (18%)	20%	1 (6%)	10%	3 (18%)	18%	15
	7.5	9	4 (44%)	2070	2 (22%)	2070	2 (22%)	1070	2 (22%)	1070	11
	10	9	4 (44%)		1 (11%)		2 (22%)		1 (11%)		12
APPswe	9 - 12	26	3 (12%)		2 (8%)		1 (4%)		2 (8%)		0
	13 - 16	30	1 (3%)	6%	11 (37%)	26%	0 (3%)	2%	10 (33%)	22%	0
	17 - 20	16	0 (0%)		6 (38%)		0 (0%)		4 (25%)		0
C57BL/6 (wild- type)	2.5 - 16	27									

Supplemental Table 1 – Overview of the animal cohorts studied by Aβ-PET and TSPO-PET and their frequency of asymmetry in Aβ-PET